Literature DB >> 15359271

Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen.

Terrie-Anne Cock1, Jonathan Back, Florent Elefteriou, Gérard Karsenty, Philippe Kastner, Susan Chan, Johan Auwerx.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) controls adipogenesis and metabolism. We demonstrate here that the absence of PPARgamma in fat has potent osteogenic activities, which affect haematopoiesis. The congenital absence of PPARgamma in fat of lipodystrophic PPARgamma(hyp/hyp) mice, strongly enhanced bone mass and consequentially reduced the bone-marrow cavity. Consistent with this, PPARgamma(hyp/hyp) mice had a significant decrease in bone marrow cellularity and resorted to extramedullary haematopoiesis in the spleen to maintain haematopoiesis. Our data indicate that antagonizing PPARgamma activity in fat could be an effective way to combat osteoporosis and suggest that haematopoietic function should be scrutinized in lipodystrophic subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15359271      PMCID: PMC1299154          DOI: 10.1038/sj.embor.7400254

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  30 in total

1.  PU.1 determines the self-renewal capacity of erythroid progenitor cells.

Authors:  Jonathan Back; Andrée Dierich; Corinne Bronn; Philippe Kastner; Susan Chan
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

2.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.

Authors:  Toru Akune; Shinsuke Ohba; Satoru Kamekura; Masayuki Yamaguchi; Ung-Il Chung; Naoto Kubota; Yasuo Terauchi; Yoshifumi Harada; Yoshiaki Azuma; Kozo Nakamura; Takashi Kadowaki; Hiroshi Kawaguchi
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

3.  Leptin stimulates fetal and adult erythroid and myeloid development.

Authors:  A A Mikhail; E X Beck; A Shafer; B Barut; J S Gbur; T J Zupancic; A C Schweitzer; J A Cioffi; G Lacaud; B Ouyang; G Keller; H R Snodgrass
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

4.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.

Authors:  A Meirhaeghe; L Fajas; N Helbecque; D Cottel; P Lebel; J Dallongeville; S Deeb; J Auwerx; P Amouyel
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

Review 5.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

6.  Extramedullary hematopoiesis assessment in a patient with osteopetrosis.

Authors:  C Caluser; A Scott; H Macapinlac; S Yeh; N Rosenfelt; B Farid; H M Abdel-Dayem; S M Larson; H Kalaigian
Journal:  Clin Nucl Med       Date:  1995-01       Impact factor: 7.794

7.  Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts.

Authors:  S Ogawa; T Urano; T Hosoi; M Miyao; S Hoshino; M Fujita; M Shiraki; H Orimo; Y Ouchi; S Inoue
Journal:  Biochem Biophys Res Commun       Date:  1999-06-24       Impact factor: 3.575

8.  Life without white fat: a transgenic mouse.

Authors:  J Moitra; M M Mason; M Olive; D Krylov; O Gavrilova; B Marcus-Samuels; L Feigenbaum; E Lee; T Aoyama; M Eckhaus; M L Reitman; C Vinson
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

9.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.

Authors:  I Shimomura; R E Hammer; J A Richardson; S Ikemoto; Y Bashmakov; J L Goldstein; M S Brown
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

10.  A role for leptin and its cognate receptor in hematopoiesis.

Authors:  B D Bennett; G P Solar; J Q Yuan; J Mathias; G R Thomas; W Matthews
Journal:  Curr Biol       Date:  1996-09-01       Impact factor: 10.834

View more
  49 in total

Review 1.  Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells.

Authors:  Hiroshi Kawaguchi; Toru Akune; Masayuki Yamaguchi; Shinsuke Ohba; Naoshi Ogata; Ung-il Chung; Naoto Kubota; Yasuo Terauchi; Takashi Kadowaki; Kozo Nakamura
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

2.  Bone seems susceptible to range of drugs.

Authors:  Charlotte Schubert
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

Review 3.  Regulation of bone remodeling by the central and peripheral nervous system.

Authors:  Florent Elefteriou
Journal:  Arch Biochem Biophys       Date:  2008-03-23       Impact factor: 4.013

4.  Deletion of PPARγ in Mesenchymal Lineage Cells Protects Against Aging-Induced Cortical Bone Loss in Mice.

Authors:  Jay Cao; Kehong Ding; Guodong Pan; Raysa Rosario; Yun Su; Yonggang Bao; Hongyan Zhou; Jianru Xu; Meghan E McGee Lawrence; Mark W Hamrick; Carlos M Isales; Xingming Shi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-04-17       Impact factor: 6.053

Review 5.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

Review 6.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

Review 7.  From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.

Authors:  Stavros C Manolagas
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 8.  Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages.

Authors:  Lucía Fuentes; Tamás Roszer; Mercedes Ricote
Journal:  Mediators Inflamm       Date:  2010-05-20       Impact factor: 4.711

9.  Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.

Authors:  Renata Bocciardi; Roberto Ravazzolo
Journal:  PPAR Res       Date:  2010-06-16       Impact factor: 4.964

10.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.